-
-
Pharma & Human Health -
Pharma & Human Health -
Editor's Choice -
Editor's Choice
Editor’s Choice
Editor's Choice
Modelling Biology Using Graph Language
Abstract: At Eagle Genomics, we use graph databases to model the biological domain. This enables the scientist to access the relevant information and insight they are looking for in a number of industries, including pharmaceuticals, healthcare […]
Editor's Choice
Compositional Data Analysis Approaches to Improve Microbiome Studies – From Collection to Conclusions
Abstract: As vast amounts of high-throughput data are generated from sequencing the microbiome, suitable analysis approaches are needed to effectively evaluate the data and reach robust conclusions to power studies incorporating microbiome research questions. Sequencing […]
Editor's Choice
New Statistical Method Identifies Cytokines that Distinguish Stool Microbiomes
Abstract: A wide class of formal statistical methods exist that can be developed and applied to microbiome data. In this talk we present a statistical regression model. Regressing an outcome or dependent variable onto a set […]
In Case you Missed it:
Editor's Choice
New Statistical Method Identifies Cytokines that Distinguish Stool Microbiomes
Abstract: A wide class of formal statistical methods exist that can be developed and applied to microbiome data. In this talk we present a statistical regression model. Regressing an outcome or dependent variable onto a set […]
Finance
Intralytix Receives Multimillion-Dollar Clinical Trial Award From NIAID to Manage Shigella Infections in Humans
Intralytix, Inc. announced that it has received a multimillion-dollar grant (AI 148054) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), for the clinical development of its bacteriophage therapy […]
Editor's Choice
Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy
Today, Rebiotix and Ferring Pharmaceuticals announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome-based treatment, RBX2660. These preliminary positive efficacy findings mark an important milestone, advancing RBX2660 in its […]
Editor's Choice
Microbiome after coronavirus: Investing in the power of microbes
The COVID-19 crisis is causing immense suffering and an appalling death toll. It has also dramatically impacted our personal and professional lives, and individuals, businesses and investors can’t wait to get back to normalcy. However, […]
Editor's Choice
Until next Probiota, savor the learnings of Probiota Dublin 2020
Probiota is set with the ambition to connect business and science of the microbiome space, build community, start conversations and inspire innovation, as very well expressed by Nathan Gray from William Reed. Probiota this year […]
